Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Sołek P et al. | 2022 | intact cell/cell culture, HeLa cells (human adenocarcinoma cell line) and DU 145 cells (human prostate cancer cell line) | magnetic field, signals/pulses, 50/60 Hz, also other exposures without EMF, co-exposure | - |
Nindl G et al. | 1997 | intact cell/cell culture, Jurkat cells (clone E6-1; T-lymphocyte hybridoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 0.1–1.8 mT |
Jacobi-Elizondo JS et al. | 2001 | intact cell/cell culture, L5178Y-R cells (mouse lymphoma cell line), animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 1 mT |
Shibaki R et al. | 2022 | intact cell/cell culture, MES-SA and MES-SA/DxS cells (human uterine sarcoma cell lines) | magnetic field, 50/60 Hz, co-exposure, also other exposures without EMF | - |
Percherancier Y et al. | 2015 | intact cell/cell culture, NIH3T3 cells (mouse fibroblasts) | magnetic field, 50/60 Hz | 0.4–1 mT |
Saito A et al. | 2009 | intact cell/cell culture, P19 cells (mouse embryonal carcinoma cells) | magnetic field, low frequency, 50/60 Hz | 1–10 mT |
Morabito C et al. | 2010 | intact cell/cell culture, PC-12 cells | magnetic field, low frequency, 50/60 Hz | 0.1–1 mT |
Opler M et al. | 1997 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, 50/60 Hz | 6.7–8 µT |
Hwang YH et al. | 2011 | intact cell/cell culture, RBL-2H3 (rat basophilic leukemia cells) | magnetic field, low frequency, 50/60 Hz | 0.1–1 mT |
Yamaguchi DT et al. | 2002 | intact cell/cell culture, ROS 17/2.8 (osteoblast-like cells) and MC3T3-E1 cells (mouse osteoblast-like cells) | magnetic field, low frequency, 50/60 Hz, therapeutic/medical device | 0.6–1.25 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.